Geron Corp. buy melinda
Start price
03.09.12
/
50%
€2.25
Target price
04.03.13
€2.80
Performance (%)
-51.11%
End price
04.03.13
€1.10
Summary
This prediction ended on 04.03.13 with a price of €1.10. Massive losses of -51.11% were the result for the BUY prediction by melinda. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Geron Corp. | 2.966% | 2.966% | -68.414% | -47.304% |
| iShares Core DAX® | 0.734% | 1.458% | 17.980% | 65.292% |
| iShares Nasdaq 100 | -2.686% | -0.146% | 3.810% | 97.467% |
| iShares Nikkei 225® | -2.261% | -2.729% | 11.679% | 39.755% |
| iShares S&P 500 | -1.346% | 0.467% | 1.970% | 61.093% |
Comments by melinda for this prediction
In the thread Geron Corp. diskutieren
pharma
Geron Corp ist ein biopharmazeutisches Unternehmen, das therapeutische Klasse für Krebs entwickelt (Brust, Lunge)
(Laufzeit überschritten)